Reply from authors re: Robert S. Svatek. Long-term outcomes of the FinnBladder-4 study. Eur Urol 2015;68:618-9: which type of maintenance matters?
Department of Urology, Helsinki University Hospital, Helsinki, Finland. Electronic address: riikka.jarvinen@hus.fi.
Riikka
R
Järvinen
Department of Surgery, Hyvinkää Hospital, Hyvinkää, Finland.
Eero
E
Kaasinen
Department of Urology, Seinäjoki Central Hospital, Seinäjoki, Finland.
Timo
T
Marttila
Department of Urology, Helsinki University Hospital, Helsinki, Finland.
Erkki
E
Rintala
Department of Urology, Turku University Hospital, Turku, Finland.
Peter
P
Boström
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001500:BCG Vaccine / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage*; D008297:Male; D016685:Mitomycin / Q000008:administration & dosage*; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D001500:BCG Vaccine; D016898:Interferon-alpha; D016685:Mitomycin